Patents by Inventor J. Jeffry Howbert

J. Jeffry Howbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-acylaminopropanamides as tachykinin receptor antagonists
    Patent number: 5565568
    Abstract: This invention provides a series of novel substituted propanamides which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: October 15, 1996
    Assignee: Eli Lilly and Company
    Inventors: Sung-Yong S. Cho, Philip A. Hipskind, J. Jeffry Howbert, Brian S. Muehl, James A. Nixon
  • Methods of inhibiting physiological conditions associated with an excess of bradykinin
    Patent number: 5545641
    Abstract: A method of inhibiting a physiological condition associated with an excess of bradykinin comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: August 13, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Naphthyl bradykinin receptor antagonists
    Patent number: 5514675
    Abstract: This invention provides methods of treating a physiological disorder associated with an excess of bradykinins in a mammal which comprises administering to a mammal in need of said treatment a compound selected from a series of substituted dihydronaphthalenes and naphthalenes.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: May 7, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Use of bengothiophenls to treat pain due to an excess of neuropeptide y
    Patent number: 5504094
    Abstract: A method of inhibiting a physiological disorder associated with an excess of neuropeptide Y or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: August 21, 1995
    Date of Patent: April 2, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Naphthyl tachykinin receptor antagonists to treat physiological conditions
    Patent number: 5491140
    Abstract: This invention provides methods of treating a physiological disorder associated with an excess of tachykinins in a mammal which comprises administering to a mammal in need of said treatment a compound selected from a series of substituted dihydronaphthalenes and naphthalenes.
    Type: Grant
    Filed: June 30, 1994
    Date of Patent: February 13, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
  • Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
    Patent number: 5399565
    Abstract: Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.
    Type: Grant
    Filed: November 12, 1993
    Date of Patent: March 21, 1995
    Assignee: Eli Lilly and Company
    Inventors: Beverley Greenwood, David R. Helton, J. Jeffry Howbert, Steven J. Mitan, Kurt Rasmussen
  • Antitumor compositions and methods of treatment
    Patent number: 5354778
    Abstract: This invention provides certain N-phenyl-N'-substituted phenylsulfonylureas compounds, formulations, and a method for treating susceptible neoplasms in mammals using the sulfonylurea compounds.
    Type: Grant
    Filed: March 26, 1993
    Date of Patent: October 11, 1994
    Assignee: Eli Lilly and Company
    Inventors: James E. Ray, John E. Toth, J. Jeffry Howbert
  • Antitumor compositions and methods of treatment
    Patent number: 5302724
    Abstract: This invention provides certain sulfonamide compounds, formulations and method of use of certain sulfonamide compounds in treating susceptible neoplasms.
    Type: Grant
    Filed: April 29, 1992
    Date of Patent: April 12, 1994
    Assignee: Eli Lilly and Company
    Inventors: J. Jeffry Howbert, Fariborz Mohamadi, Michael M. Spees
  • Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations thereof
    Patent number: 5300514
    Abstract: Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.
    Type: Grant
    Filed: March 18, 1993
    Date of Patent: April 5, 1994
    Assignee: Eli Lilly and Company
    Inventors: Raymond F. Brown, J. Jeffry Howbert, Karen L. Lobb, David A. Neel, Jon K. Reel, Beverley Greenwood
  • Antitumor compositions and methods of treatment
    Patent number: 5234955
    Abstract: This invention provides certain N-phenyl-N'-substitutedphenylsulfonylureas compounds, formulations, and a method for treating susceptible neoplasms in mammals using the sulfonylurea compounds.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: August 10, 1993
    Assignee: Eli Lilly and Company
    Inventors: James E. Ray, John E. Toth, J. Jeffry Howbert
  • Antitumor compositions and methods of treatment
    Patent number: 5216026
    Abstract: A method is provided for treating a susceptible neoplasm in mammals which comprises administering to a mammal in need of said treatment an effective amount for treating the neoplasm of the compound N-[[(4-chlorophenyl)amino]carbonyl]-1-butanesulfonamide or a pharmaceutically acceptable salt thereof, wherein said neoplasm is selected from the group consisting of ovarian, non-small cell lung, gastric, pancreatic, renal cell, breast, colorectal, small-cell lung, melanoma, head and neck, Kaposi's sarcoma, and rhabdomyosarcoma.
    Type: Grant
    Filed: July 17, 1990
    Date of Patent: June 1, 1993
    Assignee: Eli Lilly and Company
    Inventor: J. Jeffry Howbert